Rubicon Research IPO Details, GMP Price, Date, Review

Rubicon Research IPO details Today : Rubicon Research IPO details Today is Open on [.] 2024 and Close on [.] 2024. Rubicon Research IPO to Raise [.] shares (Approx ₹[.] Cr) via IPO. The Fresh issue of [.] shares (Approx ₹[.] Cr). 

We are a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of six listed Indian companies assessed by F&S, and our Company), we are the only Indian pharmaceutical player with a complete focus on regulated markets.

We believe our multi-disciplinary, data-driven, and return on investment (“ROI”) centric product selection framework is geared towards identifying sustainable opportunities for new product development. We identify and pursue such opportunities in a manner that provides us a competitive advantage by leveraging our development, manufacturing,
and commercialization capabilities to create and grow our share of the market.

Our branded products, i.e. products prescribed by brand name, are marketed through our recently acquired subsidiary, Validus Pharmaceuticals LLC (“Validus”). Non-branded products, i.e. those for which a prescription with the specific active ingredient (but not a specific brand name) is required, are marketed by our wholly owned subsidiary AdvaGen Pharma Ltd. (“AdvaGen Pharma”) and selectively via third-party distributors.

To develop our marketing and promotion channels for our branded products pipeline, in 2024 we acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. Validus has two brand name products in the CNS therapy area (Equetro® and Marplan®).

We have two US FDA inspected R&D facilities – one each in India and Canada, and two manufacturing facilities In India with multiple accreditations from multiple regulatory agencies such as US FDA, Food and Drugs Administration, Maharashtra (WHO-GMP accreditation) and Health Canada. Our facilities are equipped with a range of drug development and manufacturing capabilities across dosage forms.

We believe we have a robust product selection framework based on a data-driven, multi-disciplinary and ROI centric selection approach, geared towards consistently identifying opportunities for new product development.

We identify opportunities that leverage our competitive strengths, development, manufacturing, and commercialization capabilities, and pursue them in a timely manner to generate sustainable revenue and margins, often from establishing a first-mover or early-mover advantage.

We have worked on various drug delivery technology platforms including barrier membrane technology, matrix systems and osmotic systems. We have developed nine proprietary technologies for drug delivery and the two most notable among them are:

• RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies.
• RubiReten – a gastro-retentive system for drugs with poor solubility and a limited window of absorption.

Object of the Issue

1. Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our Company.
2. Funding inorganic growth through unidentified acquisitions and other strategic initiatives.
3. General corporate purposes.

Our Company Promoters

1. Pratibha Pilgaonkar
2. Sudhir Dhirendra Pilgaonkar
3. Parag Suganchand Sancheti
4. Surabhi Parag Sancheti
5. Sumant Sudhir Pilgaonkar
6. General Atlantic Singapore RR Pte. Ltd.

Qualitative Factors

• We are the fastest growing Indian pharmaceutical company amongst our peers and the only Indian company focused completely on the US market.
• Our data-driven product selection framework has allowed us to build a product portfolio with a combination of new and specialty products allowing us to withstand pricing pressures.
• Our R&D capabilities and continuing investment allow us to pursue complex products that offer strong revenue opportunities.
• Robust sales and distribution capabilities in the US.
• Strong track record of compliance combined with expertise in cost effective manufacturing.
• Experienced and entrepreneurial management team with a proven track record and marquee private equity investor.

Comparison of Accounting Ratios with Listed Peer Group Companies

• Rubicon Research
• Sun Pharmaceutical Industries Limited
• Aurobindo Pharma Limited
• Zydus Lifesciences Limited
• Strides Pharma Science Limited
• Dr. Reddy’s Laboratories Limited
• Alembic Pharmaceuticals Limited

Also Read: Hero fincorp IPO

Rubicon Research Company Contact Details

MedOne House, B-75,
Road No. 33, Wagle Estate,
Thane West- 400 604,
Maharashtra, India.
Contact Person: Deepashree Tanksale
Telephone: 022 61414 000
Email: investors@rubicon.co.in
Website: www.rubicon.co.in

Rubicon Research IPO Registrar

Link Intime India Private Limited
C-101, 247 Park
L.B.S. Marg, Vikhroli (West), Mumbai 400
083, Maharashtra, India
Tel: +91 81081 14949
E-mail: rubicon.ipo @linkintime.co.in
Website: www.linkintime.co.in
Investor Grievance ID: rubicon.ipo@linkintime.co.in
Contact Person: Shanti Gopalkrishnan